{Reference Type}: Journal Article
{Title}: Cystic fibrosis-related diabetes: Prevalence, screening, and diagnosis.
{Author}: Khare S;Desimone M;Kasim N;Chan CL;
{Journal}: J Clin Transl Endocrinol
{Volume}: 27
{Issue}: 0
{Year}: 2022 Mar
暂无{DOI}: 10.1016/j.jcte.2021.100290
{Abstract}: Cystic fibrosis-related diabetes (CFRD) is the most common comorbidity in patients with cystic fibrosis (CF). Prevalence of CFRD increases with age and is greater with severe mutations. Other risk factors associated with CFRD are female sex, pancreatic insufficiency, liver disease, need for gastrostomy tube feedings, history of bronchopulmonary aspergillosis, and poor pulmonary function. CFRD is related to worse clinical outcomes and increased mortality. Early diagnosis and treatment have been shown to improve clinical outcomes. Screening for CFRD is recommended with an annual oral glucose tolerance test (OGTT) starting at age 10 years. Diagnosis of CFRD is made by standard American Diabetes Association (ADA) criteria during baseline health. CFRD can also be diagnosed in individuals with CF during acute illness, while on enteral feeds, and after transplant. In this review we will discuss the epidemiology of CFRD and provide an overview of the advantages and pitfalls of current screening and diagnostic tests for CFRD.